Dr. Reddy’s Laboratories Limited announced its audited consolidated financial results for the quarter and year ended March 31, 2026, following a Board meeting on May 12, 2026. The company reported a consolidated revenue of ₹75,162 million for the fourth quarter of FY26, representing a 13.9% decrease from the previous quarter’s ₹87,268 million and an 11.6% decline from ₹85,060 million in the same period last year. Net profit for the quarter stood at ₹2,205 million, marking a significant 81.5% drop from ₹11,896 million in Q3 FY26 and an 86.1% decrease compared to ₹15,873 million in Q4 FY25. This performance was impacted by various one-off items, including a shelf stock adjustment related to lenalidomide, impairment of CAR-T assets, and provisions for VAT liability. Despite quarterly headwinds, the full-year revenue for FY26 grew by 3.2% to ₹335,933 million. The Board also recommended a final dividend of ₹8 per equity share for the financial year 2025-26.

Dr. Reddy’s Laboratories Limited is a prominent global pharmaceutical company headquartered in Hyderabad, India, dedicated to providing a wide range of affordable and innovative medicines. The company operates through several key segments, including Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and others, with a strong presence in major markets such as North America, Europe, India, and emerging markets. Its diverse portfolio encompasses generics, biosimilars, differentiated formulations, and active pharmaceutical ingredients. Dr. Reddy’s continues to focus on long-term growth through strategic franchises in innovation and consumer health while optimizing its base business.